Novartis Announces 14 Innovative Medicines and New Indications Included in China's 2022 National Reimbursement Drug List

Gelonghui January 19th :: The WeChat Official Account of "Novartis Group" announced that seven products and new indications from Novartis have successfully been included in the 2022 National Medical Insurance Drug Catalogue in China. These include Ocrevus (Ofatumumab Injection), Cosentyx (Secukinumab Injection), Xolair (Omalizumab for Injection), Tafinlar (Dabrafenib Mesylate Capsules), Mekinist (Trametinib Tablets), Afinitor (Everolimus Tablets), and Revolade (Eltrombopag Olamine Tablets). Additionally, the existing indications within the catalogue for Mayzent (Siponimod Tablets), Gilenya (Fingolimod Hydrochloride Capsules), Zykadia (Ceritinib Capsules), Sandostatin (Octreotide Acetate for Injection Microspheres), Votrient (Pazopanib Tablets), Simbrinza (Brinzamide Brimonidine Eye Drops), and Brinzolamide Timolol Eye Drops have all been successfully renewed.